Results 131 to 140 of about 12,771 (176)

Computational Insights into the Polypharmacological Landscape of BCR-ABL Inhibitors: Emphasis on Imatinib and Nilotinib. [PDF]

Pharmaceuticals (Basel)
Hajjo R, Sabbah DA, Alhaded R, Alquabe'h A, Bardaweel SK.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Cytogenetic response to autografting in chronic myelogenous leukemia correlates with the amount of BCR-ABL positive cells in the graft

Experimental Hematology, 2000
An important step in successful autografting of patients with chronic myelogenous leukemia is the delivery of a leukemia-free graft. We conducted this study to determine whether the cytogenetic response after autografting was correlated with the number of BCR ABL-positive cells present within the stem cell grafts.By BCR-ABL mRNA quantification, we ...
M T, Corsetti, E, Lerma, A, Dejana, M, Cavaliere, O, Figari, F, Vassallo, M, Abate, S, Luchetti, G, Piaggio, C, Parodi, G, Li Pira, F, Manca, A M, Carella   +12 more
openaire   +2 more sources

Flow cytometric assay of phosphotyrosine levels in Bcr-Abl-positive chronic myelogenous leukemias: a potential prognostic marker

Annals of Hematology, 2008
Assay of phosphotyrosine levels using flow cytometry has been used to identify patients with chronic myelogenous leukemia positive for the Bcr-Abl fusion gene. We hypothesized that clinical monitoring could identify treatment response through reductions in intragranulocyte phosphotyrosine.
Xuemei, Sun, Jianyong, Li, Junhao, Chen, Dong, Li, Leilei, Chen, Wei, Xu, Yonggong, Yang, Yujie, Wu, Pengjun, Jiang, Wei, Xie   +9 more
openaire   +2 more sources

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Annals of Hematology, 2012
Cytogenetic analyses of chronic myelogenous leukemia (CML) have been performed previously in a large number of reports, but systematical research based on large sample sizes from the Chinese population is seldom available. In this study, we analyzed the cytogenetic profiles of 1,863 Philadelphia (Ph)/BCR-ABL-positive CML patients from a research center
Qitian, Mu, Qiuling, Ma, Yungui, Wang, Zhimei, Chen, Xiangmin, Tong, Fei-Fei, Chen, Ying, Lu, Jie, Jin   +7 more
openaire   +2 more sources

[Two Ph chromosome positive chronic myelogenous leukemia patients with rare bcr/abl fusion gene].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2008
To investigate the unusual bcr/abl fusion gene structures of two Ph chromosome positive chronic myelogenous leukemia (CML) patients in chronic phase (CP).By using general M- and micro -bcr/abl specific primers respectively, bcr/abl fusion transcripts were detected by reverse transcription-polymerase chain reaction (RT-PCR).
Ya-zhen, Qin, Yan-rong, Liu, Jin-lan, Li, Hui, Wang, Yan, Chang, Jia-yu, Fu, Guo-rui, Ruan, Hui-lin, Shi, Jing-ying, Qiu, Dao-pei, Lu, Shan-shan, Chen   +10 more
openaire   +2 more sources

Concomitant JAK2 V617F-Positive Polycythemia Vera and BCR-ABL-Positive Chronic Myelogenous Leukemia Treated with Ruxolitinib and Dasatinib.

Blood, 2012
Abstract Abstract 2832 Co-occurrence of a JAK2 V617F-positive myeloproliferative neoplasm (MPN) with BCR-ABL-positive chronic myelogenous leukemia (CML) in a single patient is rare. Previous reports have suggested that the two disorders may arise independently or within the same clone, but definitive clonal analysis has ...
Eric M. Knoche, Daniel A.C. Fisher, Gregory Rippberger, Li He, Deborah M. Moore, Jonathan L. Klein, Stephen T. Oh   +6 more
openaire   +1 more source

Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in philadelphia-positive chronic myelogenous leukemia

Leukemia Research, 1992
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases.
M, Futaki, K, Inokuchi, H, Matsuoka, K, Miyake, K, Dan, T, Nomura   +5 more
openaire   +2 more sources